Overview
Cardio Diagnostics Holdings Inc. (Nasdaq: CDIO) represents the 2026 frontier of cardiovascular risk assessment through its proprietary AI-driven epigenetic mapping platform. Unlike traditional lipid panels that provide a snapshot of current blood chemistry, Cardio Diagnostics analyzes DNA methylation patterns combined with genetic markers (SNPs) to predict Coronary Heart Disease (CHD) risk. Their technical architecture utilizes deep learning models trained on multi-omic datasets to identify molecular signatures of heart disease often missed by standard care. The platform’s flagship tests, Epi+Gen CHD™ and PrecisionCHD™, integrate clinical data with molecular biology to provide a three-dimensional view of patient health. In the 2026 market, the company positions itself as a critical layer in the value-based care ecosystem, allowing clinicians to intervene years before a major cardiac event occurs. Their solution is delivered through a cloud-based provider portal that translates complex genomic data into actionable clinical insights, facilitating personalized lifestyle and pharmacological interventions. The system is designed for seamless integration with Electronic Health Records (EHR) to streamline the diagnostic workflow within existing clinical environments.